Vimta Labs Limited (VIMTALABS.BO)
- Previous Close
455.65 - Open
476.95 - Bid 448.00 x --
- Ask 450.20 x --
- Day's Range
444.90 - 476.95 - 52 Week Range
365.00 - 621.40 - Volume
1,375 - Avg. Volume
4,744 - Market Cap (intraday)
9.958B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
24.45 - EPS (TTM)
18.37 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield 2.00 (0.44%)
- Ex-Dividend Date Jun 21, 2023
- 1y Target Est
128.00
Vimta Labs Limited provides contract research and testing services in India and internationally. It offers product discovery/development, post approval/marketing, preclinical/early development/study, clinical research and development, drug life cycle management support, bioanalytical, analytical, central lab, genetically modified organisms testing, clinical diagnostics, environment testing, preclinical research and testing, food testing and analytical development, and EMI/EMC testing services, as well as IND/505 (b)(2) enabling/studies; IVPT, IVRT, and IVBE studies; and testing services for dioxins and furans, trace heavy metals, label claims, radioactive isotopes, vitamins and minerals, packaging, and shelf life. The company provides solutions to agriculture, electricals and electronics, medical devices, speciality chemicals, biologics and biosimilars, environment, health and safety, nutraceuticals, water and beverages, crop care, food, packaging, clinical diagnostics, home and personal care, and pharmaceuticals industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.
vimta.com1,368
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: VIMTALABS.BO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIMTALABS.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIMTALABS.BO
Valuation Measures
Market Cap
9.96B
Enterprise Value
9.87B
Trailing P/E
24.45
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.19
Price/Book (mrq)
3.36
Enterprise Value/Revenue
3.11
Enterprise Value/EBITDA
11.09
Financial Highlights
Profitability and Income Statement
Profit Margin
12.87%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
3.21B
Net Income Avi to Common (ttm)
413.41M
Diluted EPS (ttm)
18.37
Balance Sheet and Cash Flow
Total Cash (mrq)
261.68M
Total Debt/Equity (mrq)
6.51%
Levered Free Cash Flow (ttm)
--